Precancerous Cervical LesionNCT07009327
Efficacy and Safety of Photodynamic Therapy for CIN3
A study testing ALA-PDT in people with Precancerous Cervical Lesion, run by Peking University Third Hospital at 1 site in China.
Trial summary
To investigate the efficacy and safety of photodynamic therapy (20% 5-amino-ketovalerate 630nm red light) in the treatment of cervical intraepithelial neoplasia 3(CIN 3)in women in the real world Read more about this study
- Who is it for?
- Ages 18 to 65 years, women only
- Conditions the study is for
- Precancerous Cervical Lesion
- What is being tested?
- ALA-PDT
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2024to 31 Dec 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- CIN3, photodynamic therapy was required,
- type 1 2 transformation area, colposcopy was sufficient
- the lesion boundary was completely visible
- The ECC did not indicate high-grade lesions
Who cannot join
- coexistence or suspicion of cancer;
- TCT HSIL
- involving glands
- Porphyria patients, or suspected allergic to red and blue light.
- severe medical comorbidities；
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Peking Unniversity Third Hospital
Beijing, 100191
Qin Han, 13810632686, lmlfe_lynn@126.com
About this study
Official title: Efficacy and Safety of Photodynamic Therapy for Cervical Intraepithelial Neoplasia 3(CIN3):A Multicenter Prospective Cohort Study
To investigate the efficacy and safety of photodynamic therapy (20% 5-amino-ketovalerate 630nm red light) in the treatment of cervical intraepithelial neoplasia 3(CIN 3)in women in the real world
- Conditions
- Precancerous Cervical Lesion
- Being tested
- ALA-PDT
- Keywords
- PDT, HPV, CIN 3
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ALA-PDTProcedure or surgery
use ALA_PDT to treat the disease
| Study group | Role | What they receive |
|---|---|---|
| ALA-PDT | Other | Patients choose PDT to treat the disease Receives: Procedure: ALA-PDT |
What is being measured
The primary outcome is the main question the study is designed to answer.
Efficacy of the treatment
colposcopy and biopsy will be performed one month after the treatment. Patients will be categorised as having complete remission(CR) if biopsy confirmed LSIL. If CIN 2 was found after the first course of PDT, it would be categorised as partial remission(PR). Those with the same grade were categorised as persistent disease(PD).
The proportion of CR after PDT treatment.
Measured: 1 month after the treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jun 2025
- Study start1 Jan 2024
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Precancerous Cervical LesionStudies of the same condition, open and under way.
- More trials run by Peking University Third HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Peking University Third Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Qin Han, Study chair, Peking Unniversity Third Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07009327
- Sponsor's protocol ID
- PDT-CIN3
- Other IDs
- 2022YFB3604704
- Status last verified
- May 2025
- First submitted
- 13 May 2025
- Last updated
- 6 Jun 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Chinese women attach great importance to privacy issues related to sex and do not accept the disclosure of their information
Study at a glance
From the registry record, last updated by the sponsor on 6 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Safety of Photodynamic Therapy for Cervical Intraepithelial Neoplasia 3(CIN3):A Multicenter Prospective Cohort Study
- ClinicalTrials.gov ID
- NCT07009327
- Acronym / sponsor ID
- PDT-CIN3
- Conditions
- Precancerous Cervical Lesion
- Keywords
- PDT, HPV, CIN 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Peking University Third HospitalUniversity, hospital or other
- Study start
- 1 Jan 2024 (actual)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 6 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To investigate the efficacy and safety of photodynamic therapy (20% 5-amino-ketovalerate 630nm red light) in the treatment of cervical intraepithelial neoplasia 3(CIN 3)in women in the real world
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| ALA-PDT | Other | Procedure: ALA-PDTPatients choose PDT to treat the disease |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- CIN3, photodynamic therapy was required,
- type 1 2 transformation area, colposcopy was sufficient
- the lesion boundary was completely visible
- The ECC did not indicate high-grade lesions
Key exclusion criteria (5 listed)
- coexistence or suspicion of cancer;
- TCT HSIL
- involving glands
- Porphyria patients, or suspected allergic to red and blue light.
- severe medical comorbidities；
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ALA-PDTuse ALA_PDT to treat the disease | Procedure or surgery | ALA-PDT |
Primary outcome
Efficacy of the treatment
Time frame: 1 month after the treatment
colposcopy and biopsy will be performed one month after the treatment. Patients will be categorised as having complete remission(CR) if biopsy confirmed LSIL. If CIN 2 was found after the first course of PDT, it would be categorised as partial remission(PR). Those with the same grade were categorised as persistent disease(PD). The proportion of CR after PDT treatment.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jun 2025.
- Individual participant dataSharing planned: No. Chinese women attach great importance to privacy issues related to sex and do not accept the disclosure of their information
Related trials for Precancerous Cervical Lesion
Not yet recruitingObservational study
Clinical Audit of Cervical Cytology Services in an Early Cancer Detection Unit
Cervical Intraepithelial Neoplasia, Uterine Cervical Neoplasms
Active, not recruitingObservational study
Comparison of TLC (Total Leucocyte Count), Neutrophils and Monocytes in Oral Squamous Cell Carcinoma and Pre-malignant Disorders
Oral Squamous Cell Carcinoma (OSCC), Premalignant Lesion
Active, not recruitingObservational study
Predictive Biomarkers for Precision Management of Pre-cancerous Cervical Neoplasia
HSIL, High Grade Squamous Intraepithelial Lesion, DNA Methylation
Active, not recruitingEarly Phase 1
Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders
Dysplasia, Lip and Oral Cavity Carcinoma
Not yet recruiting
Papilozumib Vaginal Gel for Exocervical Mucosal Restoration in Women With Human Papillomavirus (HPV)
Human Papillomavirus Infection, Human Papillomavirus Infections
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Qin Han study chair
Peking Unniversity Third Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing ALA-PDT in people with Precancerous Cervical Lesion, run by Peking University Third Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Qin Han (13810632686, Lmlfe_lynn@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Efficacy of the treatment (time frame: 1 month after the treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jun 2025.